Non-Hodgkin lymphoma - Armitage, J. O.; Gascoyne, R. D.; Lunning, M. A.; Cavalli, F. (Lancet, 2017)

Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience - Salles, G. (Adv. Ther., 2017)

Noncellular immune therapies for non-Hodgkin lymphoma - Herrera, A. F. (Hematol. Oncol. Clin. N. Am., 2019)

Revised response criteria for malignant lymphoma - Cheson, B. D. (J. Clin. Oncol., 2007)

Response assessment in Waldenstrom macroglobulinaemia: update from the VIth international workshop - Owen, R. G. (Br. J. Haematol., 2013)

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte - Coiffier, B. (Blood, 2010)

Gagniuc, P. Markov Chains: From Theory to Implementation and Experimentation 1–256 (Wiley, 2017). ISBN 978-1-119-38755-8.

Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study - Casulo, C. (J. Clin. Oncol., 2015)

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation - Biagi, J. J.; Seymour, J. F. (Blood, 2002)

Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001–2010 - Bassig, B. A. (Cancer Epidemiol., 2016)

Diffuse large B-cell lymphoma - Li, S.; Young, K. H.; Medeiros, L. J. (Pathology, 2018)

Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's haematological malignancy research network - Smith, A. (Br. J. Cancer, 2015)

Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution - Lee, M. Y.; Tan, T. D.; Feng, A. C.; Liu, M. C. (Am. J. Hematol., 2006)

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project - Perry, A. M. (Haematologica, 2016)

Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies - Matsuo, K. (Cancer Sci., 2004)

Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants - Chen, C. H. (J. Formos Med. Assoc., 2007)

Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan - Chen, C. L. (J. Hepatol., 2015)

The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma - Huang, C. E. (J. Viral Hepat., 2017)

Infectious agents and lymphoma development: molecular and clinical aspects - Ferreri, A. J.; Ernberg, I.; Copie-Bergman, C. (J. Intern. Med., 2009)

A large-scale seroprevalence of Epstein-Barr virus in Taiwan - Chen, C. Y.; Huang, K. Y.; Shen, J. H.; Tsao, K. C.; Huang, Y. C. (PLoS ONE, 2015)

International Agency for Research on Cancer, Swerdlow S. H. (ed) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edn (2017).

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation - Hamadani, M. (Biol. Blood Marrow Transpl., 2014)

Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma - Modvig, L.; Vase, M.; d'Amore, F. (Br. J. Haematol., 2017)